Mirum Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Mirum Pharmaceuticals, Inc. on June 12, 2023. The record date for the meeting was April 17, 2023, with 38,030,661 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors - Three Class I directors were elected to serve until the 2026 Annual Meeting.
- Lon Cardon: 30,587,478 votes For; 410,063 votes Withheld; 3,228,927 Broker Non-Votes.
- William Fairey: 30,362,034 votes For; 635,507 votes Withheld; 3,228,927 Broker Non-Votes.
- Timothy Walbert: 27,482,518 votes For; 3,515,023 votes Withheld; 3,228,927 Broker Non-Votes.
- Proposal 2: Ratification of Auditors - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Results: 34,194,852 votes For; 3,376 votes Against; 28,240 Abstentions; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (Lon Cardon, William Fairey, Timothy Walbert) through the 2026 Annual Meeting.
- Confirm the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2023.
- Note the significant number of broker non-votes (3,228,927) on the director election proposals, which may indicate shares held in street name where brokers lacked discretionary voting authority.